Stay updated with breaking news from General Inception. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
It’s called a pangenome, and it could explain the DNA that makes each of us unique.
/PRNewswire/ -- OmniSync has been awarded a 5-year Phase III commercialization contract by the Office of Small Business Innovation Research (SBIR)/Small...
General Inception, the first-ever Igniter, today announced its multi-year strategic partnership with SATT Paris-Saclay to identify and help scientific innovators from its member research laboratories
/PRNewswire/ -- OmniSync Incorporated announces that it has been selected by AFWERX for a SBIR Phase II contract in the amount of $757,428 focused on adapting...